Vor Biopharma’s (VOR) “Neutral” Rating Reaffirmed at HC Wainwright

Vor Biopharma (NYSE:VOR)‘s stock had its “neutral” rating restated by equities research analysts at HC Wainwright in a research note issued on Friday, Marketbeat.com reports.

A number of other research analysts have also issued reports on VOR. Oppenheimer restated an “outperform” rating and set a $8.00 price target on shares of Vor Biopharma in a research note on Friday, March 21st. Wedbush reissued a “neutral” rating and issued a $0.40 price objective (down previously from $7.00) on shares of Vor Biopharma in a report on Thursday. Finally, Stifel Nicolaus dropped their price objective on shares of Vor Biopharma from $12.00 to $5.00 and set a “buy” rating on the stock in a research note on Friday, March 21st. Six research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $7.06.

Vor Biopharma Trading Down 5.4 %

Shares of NYSE VOR opened at $0.15 on Friday. The stock has a market capitalization of $18.89 million, a PE ratio of -0.09 and a beta of -0.21. Vor Biopharma has a 12-month low of $0.13 and a 12-month high of $1.87. The stock’s fifty day simple moving average is $0.70 and its two-hundred day simple moving average is $0.97.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. RA Capital Management L.P. boosted its position in shares of Vor Biopharma by 74.3% in the 4th quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company’s stock worth $44,007,000 after buying an additional 16,897,159 shares in the last quarter. Lynx1 Capital Management LP acquired a new stake in shares of Vor Biopharma during the 4th quarter worth about $707,000. Trustees of Columbia University in the City of New York purchased a new stake in shares of Vor Biopharma during the fourth quarter worth about $102,000. XTX Topco Ltd acquired a new stake in Vor Biopharma during the fourth quarter worth approximately $80,000. Finally, Virtu Financial LLC purchased a new stake in Vor Biopharma in the 4th quarter worth approximately $60,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.